ClinicalTrials.gg
CompletedNCT05653713Updated Nov 29, 2023

Effects of CSL324 in the Lung After Segmental Challenge

A Phase 1 interventional study of CSL324 and Placebo in Healthy Volunteers, sponsored by CSL Behring. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by CSL Behring (part of CSL Limited) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a phase 1b, randomized, double-blind, placebo-controlled study in healthy volunteers to investigate the antiinflammatory effect of pretreatment with CSL324 on response to a lipopolysaccharide (LPS) endotoxin challenge in a single lung segment. Saline will be instilled into a segment in the contralateral lung for the purpose of comparison.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.

First submitted after CSL Behring became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female volunteer.
  • Between the ages of ≥ 18 and ≤ 65 years.
  • within the range of 18 to 32 kg/m2
  • Female of nonchildbearing potential or of and willing to use a highly effective method of (in addition to male partner condom with or without spermicide)
  • Nonsmoker or an ex-smoker who has stopped smoking (including e-cigarettes or vaping devices) for > 1 year with a smoking history of \< 10 pack-years.

Exclusion criteria

Exclusion Criteria:

  • Any abnormalities in physical examination findings, (ECG) readings, safety laboratory test results, or ANC \< 2.0 × 109 cells/L.
  • History of myeloproliferative or lymphoproliferative disease.
  • Current or previous history of any condition.
  • Currently receiving any immunosuppressive or immunomodulatory therapy, or history of undergoing such therapy.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    CSL324

    Intravenous (IV) dose of CSL324

    Drug: CSL324

  • Placebo comparator
    Placebo

    IV dose of 0.9% saline

    Drug: Placebo

Interventions

  • DrugCSL324

    Single intravenous (IV) dose of CSL324

    Also known as: Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody (mAb)

  • DrugPlacebo

    IV dose of 0.9% saline

06

What researchers measure

Primary outcomes

  1. Percent reduction in mean absolute neutrophil cell counts in bronchoalveolar lavage fluid (BALF) between CSL324 and placebo

    Time frame: Obtained at 24 hours after the segmental lipopolysaccharide (LPS) challenge with endotoxin in the lung

Secondary outcomes

  1. Percent reduction in the mean change in biomarkers of neutrophil activation in BALF from Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung between CSL324 and placebo

    Biomarkers are (neutrophil elastase \[NE\], alpha \[α\] 1 antitrypsin \[AAT) complex, and myeloperoxidase \[MPO\]) in BALF

    Time frame: Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung

  2. Percent reduction in the mean change in total protein in BALF from Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung between CSL324 and placebo

    Time frame: Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung

  3. Percent reduction in the mean change in concentrations of von Willebrand factor (vWF) in BALF from Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung between CSL324 and placebo

    Time frame: Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung

  4. Percent reduction in the mean change in concentrations of surfactant protein D (SP D) in BALF from Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung between CSL324 and placebo

    Time frame: Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung

  5. Percent reduction in the mean change in concentrations of sRAGE in BALF from Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung between CSL324 and placebo

    Time frame: Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung

  6. Percent reduction in the mean change in concentrations of G CSF in BALF from Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung between CSL324 and placebo

    Time frame: Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung

  7. Percent reduction in the mean change in concentrations of VEGF A in BALF from Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung between CSL324 and placebo

    Time frame: Baseline to 24 hours after segmental LPS challenge with endotoxin in the lung

  8. Serum concentration of CSL324

    Time frame: Up to 6 days after CSL324 administration

  9. Number of subjects with antidrug antibodies (ADAs) to CSL324 in serum

    Time frame: Prior to and up to 6 days after CSL324 and placebo administration

  10. Number and percentage of subjects with treatment-emergent adverse events (TEAEs) by treatment group

    Time frame: Up to 32 days after CSL324 and placebo administration

  11. Maximum plasma concentration (Cmax)

    Time frame: Prior to and up to 6 days after CSL324 administration

  12. Time to reach Cmax (Tmax)

    Time frame: Prior to and up to 6 days after CSL324 administration

  13. Area under the plasma concentration-time curve from time 0 to 120 hours (AUC0-120h)

    Time frame: Time 0 to 120 hours after CSL324 administration

  14. Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-last)

    Time frame: Time 0 and up to 6 days after CSL324 administration

07

Study locations

1 site
  • Fraunhofer Institute for Toxicology and Experimental Medicine
    Hannover, 30625, Germany
08

References and documents

Individual participant data

Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available.

Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Jul 2023, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2022
First posted
Dec 16, 2022
StartActual
Dec 20, 2022
Primary completionActual
Jul 21, 2023
CompletionActual
Jul 21, 2023
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05653713
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Dec 20, 2022
Primary completion
Jul 21, 2023
Completion
Jul 21, 2023
Last update
Nov 29, 2023

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anumigilimab

Start the discussion